Daniel Barocas, M.D., MPH, assistant professor of Urologic Surgery at Vanderbilt University Medical Center, was recently named a representative on the Commission on Cancer.

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

Two Vanderbilt-Ingram Cancer Center (VICC) leaders have been named to a panel of the Institute of Medicine (IOM) to help shape national policies on the use of biomarkers for targeted cancer therapies.

A specific gene expression profile represents a novel, biologically relevant “signature” for identifying colon cancers with high risk of metastatic recurrence, Vanderbilt researchers have found.

Austin Kirschner, M.D., Ph.D., assistant professor of Radiation Oncology and Cancer Biology, has received the Urology Care Foundation Research Scholars Award for the study of advanced prostate cancer.

The stands inside Memorial Gymnasium are expected to resemble a sea of pink as fans don pink attire for the Vanderbilt Commodores Women’s Basketball game Sunday, Feb. 8, at noon.

Vanderbilt-Ingram Cancer Center (VICC) patient William Ostman smiled while gazing into a camera lens and declared, “I am a prostate cancer survivor.”